Country |
Not used in the past month/occasional |
Once a week or less |
2 to 6 times per week |
Daily |
Base |
Status unknown |
|---|---|---|---|---|---|---|
Czech Republic |
4 |
|
2.5 |
6.0 |
30 |
3 |
Denmark |
|
|
|
|
0 |
0 |
Germany |
2.9 |
6.0 |
|
0.8 |
48 |
8 |
Greece |
|
|
|
|
2 |
0 |
Italy |
3.7 |
|
|
|
65 |
78 |
Cyprus |
|
|
|
|
0 |
0 |
Malta |
|
|
|
|
0 |
0 |
Netherlands |
|
|
1.0 |
|
3 |
0 |
Slovenia |
|
|
|
|
0 |
0 |
Slovakia |
|
|
|
14.0 |
38 |
0 |
Finland |
|
|
|
|
2 |
1 |
Sweden |
2 |
|
|
|
3 |
1 |
Bulgaria |
|
|
|
|
2 |
0 |
|
|
|
|
|
|
|
Total |
3.5 |
26 |
18 |
5.2 |
193 |
91 |
|
|
|
|
|
|
|
Total base |
72 |
27 |
57 |
37 |
193 |
91 |
Notes: Only countries where there are clients with volatile inhalants as primary drug and/or countries supplying data are reported Where the table is left blank there are no cases (male, female or both) See also 'General notes for interpreting data' on the Explanatory notes and help page. Source: 2005 Reitox national reports - TDI outpatient treatment centres | ||||||